HLA-C and neoplasm: Indeed, this is the most significant advantage of CAR T cells over other types of adoptive cell therapy (ACT), such as tumour-infiltrating lymphocytes (TILs) and TCR therapies, especially in cases where tumour cells lose or downregulate MHC expression [1].